Lyell Immunopharma, Inc. (NASDAQ:LYEL) Position Raised by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lifted its position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 37.3% in the 3rd quarter, Holdings Channel reports. The fund owned 135,050 shares of the company’s stock after buying an additional 36,715 shares during the period. Exchange Traded Concepts LLC’s holdings in Lyell Immunopharma were worth $186,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. ProShare Advisors LLC boosted its position in shares of Lyell Immunopharma by 9.3% during the first quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock worth $109,000 after buying an additional 4,170 shares during the period. SG Americas Securities LLC raised its stake in Lyell Immunopharma by 78.1% during the 3rd quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock valued at $79,000 after acquiring an additional 25,247 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Lyell Immunopharma by 197.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock worth $58,000 after acquiring an additional 26,635 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in shares of Lyell Immunopharma in the first quarter worth $64,000. Finally, Bank of New York Mellon Corp raised its stake in shares of Lyell Immunopharma by 6.1% during the second quarter. Bank of New York Mellon Corp now owns 671,966 shares of the company’s stock valued at $974,000 after purchasing an additional 38,487 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Wall Street Analyst Weigh In

LYEL has been the topic of several recent analyst reports. Bank of America dropped their target price on Lyell Immunopharma from $9.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, June 27th. HC Wainwright restated a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a report on Monday, August 19th.

Lyell Immunopharma Stock Down 4.3 %

Shares of NASDAQ LYEL opened at $1.12 on Tuesday. Lyell Immunopharma, Inc. has a 12 month low of $1.06 and a 12 month high of $3.26. The company has a market cap of $285.53 million, a price-to-earnings ratio of -1.24 and a beta of -0.53. The business has a fifty day simple moving average of $1.31 and a 200-day simple moving average of $1.84.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Wednesday, August 7th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.02. Lyell Immunopharma had a negative net margin of 389,368.50% and a negative return on equity of 33.35%. The business had revenue of $0.01 million for the quarter. As a group, sell-side analysts expect that Lyell Immunopharma, Inc. will post -0.85 EPS for the current fiscal year.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.